This case study focuses on Novo Nordisk, a well-known Danish pharmaceutical company, which is changing the world of diabetes, obesity and hemophilia care as well as hormone replacement and growth hormone therapy. The company's key sustainability initiatives are presented through an analysis of secondary data such as websites, annual reports, books, etc. The analysis shows that Novo Nordisk makes decisions according to the "Novo Nordisk Way" and translates this decision-making philosophy into the "Triple Bottom line", a combined balance of the dimensions of sustainability: environmental, social, and economic considerations. Further, the company puts a lot of focus on behaving responsibly towards their stakeholder groups: customers, employees, communities, suppliers and investors. Novo Nordisk defines success by the solutions they bring to society in benefiting the health and well-being of people living with certain chronic diseases. They also focus on chronic diseases' prevention and broadening access to affordable care for patients worldwide.
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your Elgar Online account
-
Front Matter
-
Part 1: DEFINING A SUSTAINABILITY-DRIVEN BUSINESS STRATEGY
-
Part 2: SUSTAINABILITY-DRIVEN BUSINESS STRATEGIES IN MARKETING
-
Part 3: SUSTAINABILITY-DRIVEN BUSINESS STRATEGIES IN INNOVATION AND ENTREPRENEURSHIP
-
Part 4: SUSTAINABILITY-DRIVEN BUSINESS STRATEGIES IN OPERATIONS AND INFORMATION SYSTEMS
-
Part 5: SUSTAINABILITY-DRIVEN BUSINESS STRATEGIES IN FINANCE AND ACCOUNTING
-
Part 6: SUSTAINABILITY-DRIVEN BUSINESS STRATEGIES IN HUMAN RESOURCES
-
Part 7: SUSTAINABILITY-DRIVEN BUSINESS STRATEGIES ACROSS FUNCTIONAL AREAS IN AN ORGANIZATION
-
Part 8: CASE STUDIES ON SUSTAINABILITY-DRIVEN BUSINESS STRATEGIES
